Literature DB >> 8256748

Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.

J Morganroth1.   

Abstract

Antiarrhythmic drug-induced ventricular tachyarrhythmias have traditionally been identified on the basis of prolongation of the QT interval and the appearance of undulating peaks of sequential QRS complexes and T waves that give the tachycardia a "twisting" aspect (so-called torsades de pointes). It is now understood, however, that a precise lengthening of the QT interval is not a necessary or sufficient criterion for the development of torsades de pointes associated with drug therapy. Indeed, not all agents that have been linked with torsades de pointes cause significant lengthening of the QT interval. Moreover, sufficiently accurate determination of QT interval duration to judge a prolongation is confounded by a number of difficulties, including considerable intraindividual variability. It is possible that the development of abnormal giant U waves may be involved in the genesis of these tachyarrhythmias. Such U waves are believed to represent the summation of early afterdepolarizations occurring throughout the myocardium. The prepause ventricular rate determines the amplitude of the U wave, and larger U waves give rise to longer and faster runs of ventricular tachycardia. These arrhythmias tend to be self-perpetuating in a bigeminal feedback pattern. At present, our knowledge base about the relation of the QT interval and torsades de pointes is grossly incomplete. More basic and clinical data are required before hard clinical judgments can be made with any precision.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8256748     DOI: 10.1016/0002-9149(93)90033-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?

Authors:  I Cavero; M Mestre; J M Guillon; E Heuillet; A G Roach
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 2.  Drugs, QT interval prolongation and ICH E14: the need to get it right.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature.

Authors:  Amy D Morris; Jennifer Chen; Elaine Lau; Jennifer Poh
Journal:  Can J Hosp Pharm       Date:  2016-06-30

4.  Short-term repeatability of electrocardiographic Tpeak-Tend and QT intervals.

Authors:  Kapuaola S Gellert; Pentti Rautaharju; Michelle L Snyder; Eric A Whitsel; Kunihiro Matsushita; Gerardo Heiss; Elsayed Z Soliman
Journal:  J Electrocardiol       Date:  2014-03-06       Impact factor: 1.438

5.  Lung function, percent emphysema, and QT duration: The Multi-Ethnic Study of Atherosclerosis (MESA) lung study.

Authors:  Hilary F Armstrong; Gina S Lovasi; Elsayed Z Soliman; Susan R Heckbert; Bruce M Psaty; John H M Austin; Jerry A Krishnan; Eric A Hoffman; Craig Johnson; Matthew J Budoff; Karol E Watson; R Graham Barr
Journal:  Respir Med       Date:  2016-12-08       Impact factor: 3.415

6.  [Perioperative treatment of patients with long QT syndrome].

Authors:  T Krönauer; P Friederich
Journal:  Anaesthesist       Date:  2015-08       Impact factor: 1.041

Review 7.  Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.

Authors:  Thomas Meyer; Karl-Heinz Boven; Elke Günther; Michael Fejtl
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

Review 8.  Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.

Authors:  Olivier Bouchaud; Patrick Imbert; Jean Etienne Touze; Alex N O Dodoo; Martin Danis; Fabrice Legros
Journal:  Malar J       Date:  2009-12-10       Impact factor: 2.979

9.  Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial.

Authors:  H Wieneke; H Conrads; J Wolstein; F Breuckmann; M Gastpar; R Erbel; Norbert Scherbaum
Journal:  Eur J Med Res       Date:  2009-01-28       Impact factor: 2.175

10.  Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.

Authors:  Stan Kutcher; Sarah J Brooks; David M Gardner; Bill Honer; Lili Kopala; Alain Labelle; Pierre Lalonde; Ashok Malla; Heather Milliken; Jorge Soni; Richard Williams
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.